Skip to content
AllergyTalk cover art

allergytalk

AllergyTalk

A Medicine , Health & Fitness and Science podcast

Good podcast? Give it some love!

About the show

AllergyTalk delivers the latest insights and evidence shaping allergy and immunology. In each bimonthly episode, leading experts break down the most impactful research and real-world takeaways from AllergyWatch®, a bimonthly publication summarizing key findings from 20 major journals in allergy and asthma.

Newest episodes

AllergyTalk Episode 65: Is an IgE Vaccine a Future Treatment For Food Allergy?

32 min

Description: In this episode, we are joined by Dr. Karla Adams, a professor of pediatrics and Program Director for the Allergy and Immunology Fellowship at Wilford Hall. We will be reviewing the July/August issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. Hosts: Gerald Lee, MD, FACAAI and Shyam Joshi, MD, FACAAI Guest: Karla Adams, MD, FACAAI This episode is eligible for CME credit: Episode 65 Target Audience: This activity is intended for primary care providers, Fellows-in-Training Learning Objectives: After completing this activity, participants should be better able to: Summarize recent key developments in the field of allergy and immunology, and assess how these findings impact clinical practice in allergy/immunology management. Demonstrate practical strategies for implementing current recommendations for allergy and immunology conditions, including specific tools and techniques that can be easily integrated into daily clinical workflows. Evaluate the effectiveness of therapy implementation in their practice and employ strategies to monitor patient outcomes in accordance with the most current allergy and immunology guidelines.   Accreditation The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Designation The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Speaker Disclosures Gerald Lee, MD, FACAAI No relevant financial relationships with ineligible companies to disclose Shyam Joshi, MD, FACAAI No relevant financial relationships with ineligible companies to disclose Karla Adams, MD, FACAAI No relev...

AllergyTalk Episode 64: Should Lymphoma Prompt an IEI Workup?

27 min

Description: In this episode, we are joined by Dr. Karla Adams, a professor of pediatrics and Program Director for the Allergy and Immunology Fellowship at Wilford Hall. We will be reviewing the July/August issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. Hosts: Gerald Lee, MD, FACAAI and Shyam Joshi, MD, FACAAI Guest: Karla Adams, MD, FACAAI This episode is eligible for CME credit: Episode 64 Target Audience: This activity is intended for primary care providers, Fellows-in-Training Learning Objectives: After completing this activity, participants should be better able to: Summarize recent key developments in the field of allergy and immunology, and assess how these findings impact clinical practice in allergy/immunology management. Demonstrate practical strategies for implementing current recommendations for allergy and immunology conditions, including specific tools and techniques that can be easily integrated into daily clinical workflows. Evaluate the effectiveness of therapy implementation in their practice and employ strategies to monitor patient outcomes in accordance with the most current allergy and immunology guidelines. Accreditation The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Designation The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Speaker Disclosures Gerald Lee, MD, FACAAI No relevant financial relationships with ineligible companies to disclose Shyam Joshi, MD, FACAAI No relevant financial relationships with ineligible companies to disclose Karla Adams, MD, FACAAI No relevant...

Anaphylaxis: Recognize & Respond Part 2: Acute Management, Prevention & the Evolving Landscape

24 min

A Practical Anaphylaxis Series: Recognize and Respond Episode 2: Acute Management, Prevention, and the Evolving Landscape Miniseries Description: Timely epinephrine use remains central to anaphylaxis management, yet barriers continue to delay treatment. Join host Dr. David Stukus and experts Drs. Syed Shahzad Mustafa and David B.K. Golden as they discuss epinephrine as first-line treatment, the limitations of antihistamines and corticosteroids, and available and emerging epinephrine delivery options. Explore how shared decision-making, patient education, and preparedness can support prompt treatment amid the evolving landscape of anaphylaxis. Host: David R. Stukus, MD, FACAAI Guests: Syed Shahzad Mustafa, MD, FACAAI, David B.K. Golden, MD, FACAAI This episode is eligible for CME credit: Acute Management, Prevention & the Evolving Landscape This podcast/vodcast miniseries is supported by an independent medical education grant from Aquestive Therapeutics, Inc. Target Audience: This activity is intended for Allergists, Advanced Practice Providers, and office staff. Learning Objectives: After completing this activity, participants should be better able to: Explain evidence-based management of anaphylaxis, including the rationale for first-line epinephrine use, barriers to timely treatment, and current U.S. and global epidemiologic trends. Accreditation The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Designation The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Speaker Disclosures: David R. Stukus, MD, FACAAI Consultant: Aquestive Therapeutics, Genentech Researcher: DBV Technologies, ARS Pharmaceuticals...

Similar podcasts

All episodes

AllergyTalk Episode 65: Is an IgE Vaccine a Future Treatment For Food Allergy?

32 min

Description: In this episode, we are joined by Dr. Karla Adams, a professor of pediatrics and Program Director for the Allergy and Immunology Fellowship at Wilford Hall. We will be reviewing the July/August issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. Hosts: Gerald Lee, MD, FACAAI and Shyam Joshi, MD, FACAAI Guest: Karla Adams, MD, FACAAI This episode is eligible for CME credit: Episode 65 Target Audience: This activity is intended for primary care providers, Fellows-in-Training Learning Objectives: After completing this activity, participants should be better able to: Summarize recent key developments in the field of allergy and immunology, and assess how these findings impact clinical practice in allergy/immunology management. Demonstrate practical strategies for implementing current recommendations for allergy and immunology conditions, including specific tools and techniques that can be easily integrated into daily clinical workflows. Evaluate the effectiveness of therapy implementation in their practice and employ strategies to monitor patient outcomes in accordance with the most current allergy and immunology guidelines.   Accreditation The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Designation The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Speaker Disclosures Gerald Lee, MD, FACAAI No relevant financial relationships with ineligible companies to disclose Shyam Joshi, MD, FACAAI No relevant financial relationships with ineligible companies to disclose Karla Adams, MD, FACAAI No relev...

AllergyTalk Episode 64: Should Lymphoma Prompt an IEI Workup?

27 min

Description: In this episode, we are joined by Dr. Karla Adams, a professor of pediatrics and Program Director for the Allergy and Immunology Fellowship at Wilford Hall. We will be reviewing the July/August issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. Hosts: Gerald Lee, MD, FACAAI and Shyam Joshi, MD, FACAAI Guest: Karla Adams, MD, FACAAI This episode is eligible for CME credit: Episode 64 Target Audience: This activity is intended for primary care providers, Fellows-in-Training Learning Objectives: After completing this activity, participants should be better able to: Summarize recent key developments in the field of allergy and immunology, and assess how these findings impact clinical practice in allergy/immunology management. Demonstrate practical strategies for implementing current recommendations for allergy and immunology conditions, including specific tools and techniques that can be easily integrated into daily clinical workflows. Evaluate the effectiveness of therapy implementation in their practice and employ strategies to monitor patient outcomes in accordance with the most current allergy and immunology guidelines. Accreditation The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Designation The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Speaker Disclosures Gerald Lee, MD, FACAAI No relevant financial relationships with ineligible companies to disclose Shyam Joshi, MD, FACAAI No relevant financial relationships with ineligible companies to disclose Karla Adams, MD, FACAAI No relevant...

Anaphylaxis: Recognize & Respond Part 2: Acute Management, Prevention & the Evolving Landscape

24 min

A Practical Anaphylaxis Series: Recognize and Respond Episode 2: Acute Management, Prevention, and the Evolving Landscape Miniseries Description: Timely epinephrine use remains central to anaphylaxis management, yet barriers continue to delay treatment. Join host Dr. David Stukus and experts Drs. Syed Shahzad Mustafa and David B.K. Golden as they discuss epinephrine as first-line treatment, the limitations of antihistamines and corticosteroids, and available and emerging epinephrine delivery options. Explore how shared decision-making, patient education, and preparedness can support prompt treatment amid the evolving landscape of anaphylaxis. Host: David R. Stukus, MD, FACAAI Guests: Syed Shahzad Mustafa, MD, FACAAI, David B.K. Golden, MD, FACAAI This episode is eligible for CME credit: Acute Management, Prevention & the Evolving Landscape This podcast/vodcast miniseries is supported by an independent medical education grant from Aquestive Therapeutics, Inc. Target Audience: This activity is intended for Allergists, Advanced Practice Providers, and office staff. Learning Objectives: After completing this activity, participants should be better able to: Explain evidence-based management of anaphylaxis, including the rationale for first-line epinephrine use, barriers to timely treatment, and current U.S. and global epidemiologic trends. Accreditation The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Designation The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Speaker Disclosures: David R. Stukus, MD, FACAAI Consultant: Aquestive Therapeutics, Genentech Researcher: DBV Technologies, ARS Pharmaceuticals...

Anaphylaxis: Recognize & Respond Part 1: Pathophysiology, Recognition & Special Populations

20 min

A Practical Anaphylaxis Series: Recognize and Respond Part 1: Pathophysiology, Recognition, and Special Populations Miniseries Description: Anaphylaxis can be difficult to recognize, with symptoms that vary across patients and age groups. Join host Dr. David Stukus and experts Drs. Jay A. Lieberman and David B.K. Golden as they explore the mechanisms underlying anaphylaxis, diagnostic criteria, and factors that influence reaction severity. Hear practical insights on recognizing atypical presentations, including reactions without skin findings, and helping patients identify when to act. Host: David R. Stukus, MD, FACAAI Guests: Jay A. Lieberman, MD, FACAAI, David B.K. Golden, MD, FACAAI This episode is eligible for CME credit: Part 1: Pathophysiology, Recognition, and Special Populations  This podcast/vodcast miniseries is supported by an independent medical education grant from Aquestive Therapeutics, Inc. Target Audience: This activity is intended for Allergists, Advanced Practice Providers, and office staff. Learning Objectives: After completing this activity, participants should be better able to: Describe the pathophysiology of anaphylaxis and how epinephrine imparts its physiologic effects. Apply validated diagnostic criteria to recognize anaphylaxis, including age-specific and rapidly evolving clinical presentations. Accreditation The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Designation The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Speaker Disclosures David R. Stukus, MD, FACAAI Consultant: Aquestive Therapeutics, Genentech Researcher: DBV Technologies, ARS Pharmaceuticals Royalties or...

AllergyTalk Episode 63: Does Hereditary Angioedema Cause Muscle Injury?

30 min

Today we are joined by Dr. Vivian Hernandez-Trujillo, the Division Director of Allergy/Immunology at Nicklaus Children’s Hospital, a Clinical Professor of Pediatrics at the Herbert Wertheim School of Medicine, and an assistant editor of Allergy Watch. We will be reviewing the May/June 2026 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.  For those currently listening to the audio version, we are now releasing video versions of AllergyTalk as well! Please visit the ACAAI YouTube channel at https://www.youtube.com/allergists For information about CME credit, head over to http://education.acaai.org/allergytalk To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: HPV vaccination is associated with lower risk of cancers among females. Association of muscle instability and long-term prophylaxis in hereditary angioedema. Prime Editing for p47(phox)-Deficient Chronic Granulomatous Disease. Recent article on TriNetX studies: https://www.science.org/content/article/medical-students-are-using-popular-research-tool-pump-out-misleading-studies  NYTimes article discussing the economics of gene therapy for rare diseases: https://www.nytimes.com/2025/09/22/health/gene-editing-rare-diseases-fda.html Please rate our podcast on Apple Podcasts and YouTube! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professio...

AllergyTalk Episode 62: Do Household Laundry Products Contribute to Asthma?

29 min

Today we are joined by Dr. Vivian Hernandez-Trujillo, the Division Director of Allergy/Immunology at Nickalus Children’s Hospital, a Clinical Professor of Pediatrics at the Herbert Wertheim School of Medicine, and an assistant editor of Allergy Watch. We will be reviewing the May/June 2026 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.  For those currently listening to the audio version, we are now releasing video versions of AllergyTalk as well! Please visit the ACAAI YouTube channel at https://www.youtube.com/allergists For information about CME credit, head over to http://education.acaai.org/allergytalk To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Identifying gaps: A survey of food allergy knowledge and management in US adults. Prevalence of KIT D816V in anaphylaxis or systemic mast cell activation. Fresh clothes, hard breaths: Laundry washing habits, detergents, softeners, and impaired respiratory functions in children with wheezing. NIH calculator: https://bst-calculater.niaid.nih.gov Please rate our podcast on Apple Podcasts and YouTube! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

AllergyTalk Episode 61 - Why All Schools Should Have Stock Albuterol

29 min

Today we are joined by Dr. Sarah Spriet, a Staff Allergist and Clinical Immunologist at Alexander T. Augusta Military Medical Center in Northern Virginia and an assistant editor of Allergy Watch. We will be reviewing the January/February 2026 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.  For those currently listening to the audio version, we are now releasing video versions of AllergyTalk as well! Please visit the ACAAI YouTube channel at https://www.youtube.com/allergists For information about CME credit, head over to http://education.acaai.org/allergytalk To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: SQ House Dust Mite Sublingual Immunotherapy Tablet in Children With Allergic Asthma: A Randomised Phase III Trial. Stock Inhalers in Chicago Public Schools: Using the RE-AIM Framework to Assess Impact. Type 2 cytokines pleiotropically modulate sensory nerve architecture and neuroimmune interactions to mediate itch.

AllergyTalk Episode 60 - How Does Dupilumab Affect Food Allergy Testing?

23 min

Welcome to another episode of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology. For today’s episode we will be reviewing articles from Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. Today we joined by Dr. Sarah, Spriet, a Staff Allergist and Clinical Immunologist at Alexander T. Augusta Military Medical Center in Northern Virginia and an assistant editor of Allergy Watch. We will be reviewing the January/February 2026 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch. Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODYmolecule. Comparative efficacy and safety of biologics and systemic immunomodulatory treatments for chronic urticaria: Systematic review and network meta-analysis Food allergy clinical course in children and adolescents treated with dupilumab for atopic dermatitis. ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

AllergyTalk Episode 59 - Can a Nasal Spray Prevent COVID?

35 min

Welcome to another episode of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology. For today’s episode we will be reviewing articles from Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. Today we joined by Dr. Shyam Joshi, an associate professor and Section Chief at Oregon Health & Science University and Associate Editor of Allergy Watch! We will be reviewing the November-December 2025 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch. Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Food-Induced Anaphylaxis: Data From the European Anaphylaxis Registry Introduction of allergenic foods after treatment with omalizumab Azelastine Nasal Spray for Prevention of SARS-CoV-2 Infections: A Phase 2 Randomized Clinical Trial. ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

AllergyTalk Episode 58: Is Zileuton the Next Treatment for Food Allergy?

27 min

Today we joined by Dr. Shyam Joshi, an associate professor and Section Chief at Oregon Health & Science University and Associate Editor of Allergy Watch! We will be reviewing the November-December 2025 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. And for those currently listening to the audio version, we are now releasing a video versions of AllergyTalk! Please visit the ACAAI YouTube channel at https://www.youtube.com/@allergists To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Paging ChatGPT: Potential and Limitations: Can ChatGPT provide parent education for oral immunotherapy?  2024 Consensus Report: A New Consensus Definition for Anaphylaxis: Anaphylaxis definition, overview, and clinical support tool: 2024 consensus report-a GA(2)LEN project.  Zileuton Prevents Food Allergen Induced Anaphylaxis in Mice: Cysteinyl leukotrienes stimulate gut absorption of food allergens to promote anaphylaxis in mice. Please rate our podcast on Apple Podcasts or YouTube! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Food Allergy Frontlines: Clarifying Diagnosis, Advancing Treatment (3-part Miniseries, Part 3)

18 min

Part 3: Biologics in IgE-Mediated Food Allergy: Expanding the Toolbox  This episode examines the growing role of biologic therapies like omalizumab in managing complex food allergies, reviewing trial data, mechanisms, and practical guidance for collaborative care. Host Gerald Lee, MD, FACAAI, is joined by Brian P. Vickery, MD, Professor of Pediatrics, Marcus Professor of Pediatric Immunology, and Chief of the Division of Allergy/Immunology at Emory University and Children’s Healthcare of Atlanta, and Julie Wang, MD, FACAAI, Professor of Pediatrics in the Division of Allergy and Immunology at the Icahn School of Medicine at Mount Sinai. For more information on this topic, please visit: Anagnostou A, Abrams EM, Carver M, et al. Development and acceptability of a decision-aid for food allergy oral immunotherapy in children. Allergy. 2025;80(1):205-214. doi:10.1111/all.16332 Anagnostou A, Greenhawt M, Shaker M, Vickery BP, Wang J. Food allergy yardstick: Where does omalizumab fit?. Ann Allergy Asthma Immunol. 2025;134(1):110-121. doi:10.1016/j.anai.2024.07.034 Bartha I, Almulhem N, Santos AF. Feast for thought: A comprehensive review of food allergy 2021-2023. J Allergy Clin Immunol. 2024;153(3):576-594. doi:10.1016/j.jaci.2023.11.918 Dantzer J, Virkud Y, Wang J, et al. Introduction of allergenic foods after treatment with omalizumab. J Allergy Clin Immunol. 2025;156(2):394-405. doi:10.1016/j.jaci.2025.05.014 Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024;390(10):889-899. doi:10.1056/NEJMoa2312382 Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedure...

Food Allergy Frontlines: Clarifying Diagnosis, Advancing Treatment (3-part Miniseries, Part 2)

12 min

Part 2: Immunotherapy for IgE-Mediated Food Allergy: OIT, SLIT & EPIT  This episode explores FDA-approved and emerging immunotherapies for food allergy—OIT, SLIT, and EPIT—highlighting their indications, efficacy, safety, and role in shared decision-making. Host Gerald Lee, MD, FACAAI, is joined by Edwin H. Kim, MD, FACAAI, Associate Professor of Pediatrics and Chief of the Division of Pediatric Allergy and Immunology at the University of North Carolina School of Medicine and Julie Wang, MD, FACAAI, Professor of Pediatrics in the Division of Allergy and Immunology at the Icahn School of Medicine at Mount Sinai. For more information on this topic, please visit: Anagnostou A, Abrams EM, Carver M, et al. Development and acceptability of a decision-aid for food allergy oral immunotherapy in children. Allergy. 2025;80(1):205-214. doi:10.1111/all.16332 Anagnostou A, Greenhawt M, Shaker M, Vickery BP, Wang J. Food allergy yardstick: Where does omalizumab fit?. Ann Allergy Asthma Immunol. 2025;134(1):110-121. doi:10.1016/j.anai.2024.07.034 Bartha I, Almulhem N, Santos AF. Feast for thought: A comprehensive review of food allergy 2021-2023. J Allergy Clin Immunol. 2024;153(3):576-594. doi:10.1016/j.jaci.2023.11.918 Dantzer J, Virkud Y, Wang J, et al. Introduction of allergenic foods after treatment with omalizumab. J Allergy Clin Immunol. 2025;156(2):394-405. doi:10.1016/j.jaci.2025.05.014 Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024;390(10):889-899. doi:10.1056/NEJMoa2312382 Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, product...

Food Allergy Frontlines: Clarifying Diagnosis, Advancing Treatment (3-part Miniseries, Part 1)

21 min

Part 1: Diagnosis, Prevention & Early Management  This episode explores how to accurately diagnose and manage food allergies in primary care, covering testing indications, referral criteria, prevention strategies, and risk stratification. Host Gerald Lee, MD, FACAAI, is joined by Brian P. Vickery, MD, Professor of Pediatrics, Marcus Professor of Pediatric Immunology, and Chief of the Division of Allergy/Immunology at Emory University and Children’s Healthcare of Atlanta, and Edwin H. Kim, MD, FACAAI, Associate Professor of Pediatrics and Chief of the Division of Pediatric Allergy and Immunology at the University of North Carolina School of Medicine. For more information on this topic, please visit: Anagnostou A, Abrams EM, Carver M, et al. Development and acceptability of a decision-aid for food allergy oral immunotherapy in children. Allergy. 2025;80(1):205-214. doi:10.1111/all.16332 Anagnostou A, Greenhawt M, Shaker M, Vickery BP, Wang J. Food allergy yardstick: Where does omalizumab fit?. Ann Allergy Asthma Immunol. 2025;134(1):110-121. doi:10.1016/j.anai.2024.07.034 Bartha I, Almulhem N, Santos AF. Feast for thought: A comprehensive review of food allergy 2021-2023. J Allergy Clin Immunol. 2024;153(3):576-594. doi:10.1016/j.jaci.2023.11.918 Dantzer J, Virkud Y, Wang J, et al. Introduction of allergenic foods after treatment with omalizumab. J Allergy Clin Immunol. 2025;156(2):394-405. doi:10.1016/j.jaci.2025.05.014 Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024;390(10):889-899. doi:10.1056/NEJMoa2312382 Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims relate...

AllergyTalk Episode 57 - What Is the Risk of Dementia With Tiotropium?

20 min

Dr. Timothy Chow, Assistant Professor at UT Southwestern and an Assistant Editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the July/August 2025 issue of AllergyWatch®. Articles Reviewed: Prenatal indoor PM2.5 exposure is associated with worse maternal asthma health and lung function Want to help your patients with food allergy anxiety? Do proximity challenges! Tiotropium initiation and dementia risk in chronic obstructive pulmonary disease Read archived issues of AllergyWatch®. Earn CME credit for listening to this episode! Free for College members! Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

AllergyTalk Episode 56 - What Is the Best Management of High Threshold Food Allergies?

25 min

Dr. Timothy Chow, Assistant Professor at UT Southwestern and an Assistant Editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the July/August 2025 issue of AllergyWatch®. Articles Reviewed: Integrated phase 1 pharmacokinetics and pharmacodynamics of epinephrine administered through sublingual film, autoinjector, or manual injection Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies Peanut oral immunotherapy in children with high-threshold peanut allergy Read archived issues of AllergyWatch®. Earn CME credit for listening to this episode! Free for College members! Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

AllergyTalk Episode 55 - What Are the Best Criteria to Identify MCAS?

33 min

Dr. Shyam Joshi, MD, Associate Professor and Section Chief at Oregon Health & Science University and Associate Editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the May/June 2025 issue of AllergyWatch®. Articles Reviewed: Outcomes of intravenous immunoglobulin treatment of immunocompromised patients with viral respiratory infections A 1-Year Weight Management Program for Difficult-to-Treat Asthma With Obesity: A Randomized Controlled Study Clustering of clinical symptoms using large language models reveals low diagnostic specificity of proposed alternatives to consensus mast cell activation syndrome criteria Read archived issues of AllergyWatch®. Earn CME credit for listening to this episode! Free for College members! Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! Speaker Disclosures: Gerald Lee, MD: No relevant financial relationships with ineligible companies to disclose Stanley Fineman, MD: No relevant financial relationships with ineligible companies to disclose Shyam Joshi, MD: Advisor: Novartis; Speaker: Novartis; Consultant: Merida Bioscience The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

AllergyTalk Episode 54 - Why Do Infections Worsen Anaphylaxis?

28 min

Dr. Shyam Joshi, MD, Associate Professor and Section Chief at Oregon Health & Science University and Associate Editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and and Dr. Stanley Fineman, MD, MBA reviewed the May/June 2025 issue of AllergyWatch®. Articles Reviewed: Association of Allergy Specialty Care and Asthma Outcomes for Medicaid-Enrolled Children Race-Specific and Race-Neutral Equations for Lung Function and Asthma Diagnosis in Black Children Anaphylactic degranulation by mast cells requires the mobilization of inflammasome components Read archived issues of AllergyWatch®. Earn CME credit for listening to this episode! Free for College members! Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! Speaker Disclosures:  Gerald Lee, MD: No relevant financial relationships with ineligible companies to disclose Stanley Fineman, MD: No relevant financial relationships with ineligible companies to disclose Shyam Joshi, MD: Advisor: Novartis; Speaker: Novartis; Consultant: Merida Bioscience The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

AllergyTalk Episode 53 - Does Primary Care and Dermatology Follow Peanut Introduction Guidelines?

29 min

Dr. Sarah Spriet, DO, Staff Allergist and Clinical Immunologist at Alexander T. Augusta Military Medical Center in Northern Virginia. She is also a Core Faculty member for the National Capital Consortium Allergy-Immunology fellowship training program and an assistant editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the January/February 2025 issue of AllergyWatch®. Articles Reviewed: Persistent cat ownership and asthma in a longitudinal study of Puerto Rican youth The SQ tree sublingual immunotherapy tablet is effective and well tolerated in children – A pivotal phase III trial Awareness and application of United States food allergy prevention guidelines among pediatricians and other clinicians Read archived issues of AllergyWatch®. Earn CME credit for listening to this episode! Free for College members! Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! Speaker Disclosures: Gerald Lee, MD: No relevant financial relationships with ineligible companies to disclose Stanley Fineman, MD: No relevant financial relationships with ineligible companies to disclose Sarah Spriet, DO: No relevant financial relationships with ineligible companies to disclose The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

AllergyTalk FIT Episode 2: I’ve Landed the Job–Now What?

25 min

Special Episode ACAAI's Fellows-in-Training Committee leaders Dr. Kylie Jungles, MD and Dr. Amber Hardeman, MD, MPH, MBA sat down with ACAAI's Practice Management Committee chair Dr. Melinda Rathkopf, MD, MBA to discuss advice on landing your first position. Continuing the conversation from Part 1, in this episode, our experts cover how to narrow down your choices, make sense of contracts and negotiations, decide whether to involve a contract lawyer, and plan a smooth transition into your next chapter. Earn CME credit for listening to this episode! Free for College members! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! Speaker Disclosures: Amber Hardeman, MD, MPH, MBA: No relevant financial relationships with ineligible companies to disclose Kylie Jungles, MD: No relevant financial relationships with ineligible companies to disclose Melinda Rathkopf, MD, MBA, FACAAI: No relevant financial relationships with ineligible companies to disclose The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

AllergyTalk FIT Episode 1: Navigating the Job Search

20 min

Special Episode ACAAI's Fellows-in-Training Committee leaders Dr. Kylie Jungles, MD and Dr. Amber Hardeman, MD, MPH, MBA sat down with ACAAI's Practice Management Committee chair Dr. Melinda Rathkopf, MD, MBA to share essential tips for fellows-in-training starting their job search. Learn how to choose the right practice setting, create a strategic job search plan, and interview with confidence. Earn CME credit for listening to this episode! Free for College members! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! Speaker Disclosures: Amber Hardeman, MD, MPH, MBA: No relevant financial relationships with ineligible companies to disclose Kylie Jungles, MD: No relevant financial relationships with ineligible companies to disclose Melinda Rathkopf, MD, MBA, FACAAI: No relevant financial relationships with ineligible companies to disclose The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Understanding the FDA Warning on Cetirizine/Levocetirizine

27 min

Special Episode On May 16, 2025, the FDA issued an alert regarding a rare but serious side effect of severe pruritus after discontinuing long-term use of cetirizine and levocetirizine. In this episode, we’ll discuss the background of this important announcement and what it means for our patients! Michael S. Blaiss, MD, Clinical Professor of Pediatrics at the Medical College of Georgia and past-president and former Executive Medical Director of the American College of Allergy, Asthma, and Immunology. He has been a consultant for multiple companies manufacturing second generation antihistamines. Dr. Blaiss was joined by host Dr. Gerald Lee, MD, FACAAI. Resources: FDA Drug Safety Communication on Cetirizine and Levocetirizine ACAAI Advice on Speaking Points Regarding FDA Alert Previous articles describing this side effect: Unbearable Pruritus After Withdrawal of (Levo)cetirizine Pruritus after discontinuation of cetirizine Make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Episode 52 - Is Treatment Refractory Wheezing a Sign of a Silent Viral infection?

23 min

Dr. Sarah Spriet, DO, Staff Allergist and Clinical Immunologist at Alexander T. Augusta Military Medical Center in Northern Virginia. She is also a Core Faculty member for the National Capital Consortium Allergy-Immunology fellowship training program and an assistant editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the January/February 2025 issue of AllergyWatch®. Articles Reviewed: A novel syndrome of silent rhinovirus-associated bronchoalveolitis in children with recurrent wheeze Effects of moderate- versus vigorous-intensity exercise training on asthma outcomes in adults Human Neutrophils Couple Nitric Oxide Production and Extracellular Trap Formation in Allergic Asthma Read archived issues of AllergyWatch®. Earn CME credit for listening to this episode! Free for College members! Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! Speaker Disclosures: Gerald Lee, MD: No relevant financial relationships with ineligible companies to disclose Stanley Fineman, MD: Researcher: Novartis, Aimmune, DBV; Speaker: Genentech Sarah Spriet, DO: No relevant financial relationships with ineligible companies to disclose The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.  

Episode 51 - Does Eosinophil Depletion Improve Eosinophilic Esophagitis?

21 min

Dr. Iris Otani, MD, an associate professor of medicine at UCSF and an assistant editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the November/December 2024 issue AllergyWatch®. Articles Reviewed: Frequencies and predictors of subcutaneous and intraosseous injection with 4 epinephrine autoinjector devices Forecasting daily total pollen concentrations on a global scale Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis Read archived issues of AllergyWatch®. Earn CME credit for listening to this episode! Free for College members! Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! Speaker Disclosures: Gerald Lee, MD: No relevant financial relationships with ineligible companies to disclose Stanley Fineman, MD: Researcher: Novartis, Aimmune, DBV; Speaker: Genentech Iris Otani, MD: Consultant: CSL Behring, Change Healthcare, Adivo Associates The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Episode 50 - Can Asthma Biologics Affect Vaccine Immunity?

26 min

Dr. Iris Otani, MD, an associate professor of medicine at UCSF and an assistant editor of AllergyWatch® and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the November/December 2024 issue AllergyWatch®. Articles Reviewed: Effect of Azithromycin on Asthma Remission in Adults With Persistent Uncontrolled Asthma: A Secondary Analysis of a Randomized, Double-Anonymized, Placebo-Controlled Trial Polyethylene glycol hypersensitivity, patient outcomes in a 7-year retrospective study Patients taking benralizumab, dupilumab, or mepolizumab have lower postvaccination SARS-CoV-2 immunity Read archived issues of AllergyWatch®. Earn CME credit for listening to this episode! Free for College members! Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! Speaker Disclosures:  Gerald Lee, MD: No relevant financial relationships with ineligible companies to disclose Stanley Fineman, MD: Researcher: Novartis, Aimmune, DBV; Speaker: Genentech Iris Otani, MD: Consultant: CSL Behring, Change Healthcare, Adivo Associates The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Episode 49 – The Mental Health Impact of Eczema and Food Allergies

22 min

Dr. Vivian Hernandez Trujillo, MD, the Division Director of allergy/immunology at Nickalus Children’s Hospital and an assistant editor of AllergyWatch and hosts Dr. Gerald Lee, MD, FACAAI and Dr. Stanley Fineman, MD, MBA reviewed the July/August 2024 issue AllergyWatch. Articles Reviewed: The mental health burden of food allergies: Insights from patients and their caregivers from the Food Allergy Research & Education (FARE) Patient Registry Stigmatization and Mental Health Impact of Chronic Pediatric Skin Disorders Bronchoconstriction damages airway epithelia by crowding-induced excess cell extrusion The speakers have the following disclosures: Dr. Lee has been a speaker for Novartis Dr. Fineman has nothing to disclose Dr. Hernandez Trujillo: Advisory Board: Aimmune, ARS, Bryn, Bayer, Enzyvant, Pfizer, Sanofi & Regeneron, Takeda Consultant: Pharming, Kaleo Speaker: CSL, Takeda, Kaleo Read archived issues of AllergyWatch®. Earn CME credit for listening to this episode! Free for College members! Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! To submit feedback, corrections, and suggestions, please email allergytalk@acaai.org! The American College of Allergy, Asthma & Immunology (ACAAI) is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.

Episode 48 - Can Blood Transfusions Trigger Food Allergy?

19 min

Welcome to Season Three of Allergytalk! Today we are joined by Dr. Vivian Hernandez Trujillo, the Division Director of allergy/immunology at Nickalus Children’s Hospital and an assistant editor of Allergy Watch. We will be reviewing the July-August issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.  For information about CME credit, head over to http://education.acaai.org/allergytalk To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: IgE to cross-reactive carbohydrate determinants (CCD) in childhood: Prevalence, risk factors, putative origins.  Activation of basophils in children with food allergies by blood from donors ingesting the corresponding food. Anti-Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency.   Please rate our podcast on Apple Podcasts! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.   Today’s speakers have the following disclosures: Dr. Lee has been a speaker for Novartis Dr. Fineman has nothing to disclose Dr. Hernandez Trujillo: Advisory Board: Aimmune, ARS, Bryn, Bayer, Enzyvant, Pfizer, Sanofi & Regeneron, Takeda Consultant/Speaker: Kaleo Consultant: Allergy & Asthma Network, Pharming Speaker: CSL, Takeda  

Pediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies miniseries Episode 3 – Long-Term Management and Prophylaxis for HAE

12 min

Host: Kristin C. Sokol, MD, MS, MPH, FACAAI Experts: Aleena Banerji, MD; Jonathan A. Bernstein, MD, FACAAI   Explore the strategies for long-term prophylaxis in pediatric HAE, including when to initiate treatment and the risks and benefits of various approaches. Transitioning care from childhood into adolescence and beyond is also discussed.   Learning Objective: After listening to this podcast episode, participants should be better able to: Employ strategies for long-term prophylaxis. References: Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767. Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533. Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3 Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022   Speaker Disclosures: Kristin C. Sokol, MD, MS, MPH, FACAAI Advisor: Sanofi, Genentech, SELF/Conde Nast   Aleena Banerji, MD Advisor: Astria, Biocryst, CSL Behring, Ionis, Intellia, Kalvista, Pharvaris, Takeda Researcher: Astria, Ionis, Intellia   Jonathan A. Bernstein, MD, FACAAI Advisor: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda Consultant: Amgen, AstraZeneca, Blueprint Medicine, Biocry...

Pediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies miniseries Episode 2 – Overcoming Barriers in HAE Treatment

20 min

Episode 2: Overcoming Barriers in HAE Treatment   Host: Kristin C. Sokol, MD, MS, MPH, FACAAI Experts: Jonathan A. Bernstein, MD, FACAAI; Timothy J. Craig, DO, FACAAI   This episode addresses the challenges of managing HAE, including treatment differences in rural vs. urban settings, barriers to care, and the importance of shared decision-making for treatment plans. Discover effective strategies for on-demand home therapy administration.   Learning Objective: After listening to this podcast episode, participants should be better able to: Create effective treatment plans for their specific population (minority, rural, urban)   References: Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767. Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533. Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3 Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022   Speaker Disclosures: Kristin C. Sokol, MD, MS, MPH, FACAAI Advisor: Sanofi, Genentech, SELF/Conde Nast   Jonathan A. Bernstein, MD, FACAAI Advisor: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda Consultant: Amgen, AstraZeneca, Blueprint Medicine, Biocry...

Pediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies Miniseries Episode 1 – Diagnosing HAE Accurately

16 min

Host: Kristin C. Sokol, MD, MS, MPH, FACAAI Experts: Aleena Banerji, MD; Timothy J. Craig, DO, FACAAI This discussion covers the key factors in accurately diagnosing HAE, including clinical history, lab testing, and the role of genetic testing in distinguishing between HAE types. Special considerations for diagnosing pediatric patients will also be discussed. Learning Objective: After listening to this podcast episode, participants should be better able to: Diagnose pediatric HAE accurately References: Allen Meadows, MD; John Anderson, MD; Richard G. Gower, MD. Challenges in the management of hereditary angioedema in urban and rural settings. Results of a United States survey. Ann Allergy Asthma Immunol 130 (2023) 760−767. Riedl MA, Johnston DT, Anderson J, Meadows JA, Soteres D, LeBlanc SB, etal. Optimization of care for patients with hereditary angioedema living in rural areas. Ann Allergy Asthma Immunol.2022;128(5):526–533. Busse PJ, Christiansen SC, Riedl MA, Banerji A, Bernstein JA, Castaldo AJ, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. JAllergyClinImmunolPract.2021;9(1):132–150.e3 Mauer M, Magerl M, Bethschel A, Aberer W, et al. The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update Allergy. 10 January 2022 Speaker Disclosures: Kristin C. Sokol, MD, MS, MPH, FACAAI Advisor: Sanofi, Genentech, SELF/Conde Nast   Aleena Banerji, MD Advisor: Astria, Biocryst, CSL Behring, Ionis, Intellia, Kalvista, Pharvaris, Takeda Researcher: Astria, Ionis, Intellia   Timothy J. Craig, DO, FACAAI Advisor: Biomarin, CSL Behring, Ionis, Kalvista, Takeda Consultant: Biocryst, Biomarin, CSL Behring, Ionis, Kalvista, Ono, Takeda Independent Contractor: Kalvista, Phavaris Researcher: Astria, Biomarin, CSL Behring, GlaxoSmithKline, Ionis, Kalvista, Phavaris, Takeda Speaker: Biomarin, CSL Behring, Kalvista, Regeneron, Takeda   This podcast miniseries is...

Episode 47: Does Food Allergy Increase Cardiovascular Risk?

24 min

Welcome to another episode of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology! For today’s episode we will be reviewing articles from Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit, head over to education.acaai.org/allergytalk. Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! CRISPR Gene-Editing Therapy for Hereditary Angioedema Reviewed by Samantha knox CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema. Longhurst HJ, Lindsay K, Petersen RS, Fijen LM, Gurugama P, Maag D, Butler JS, Shah MY, Golden A, Xu Y, Boiselle C, Vogel JD, Abdelhady AM, Maitland ML, McKee MD, Seitzer J, Han BW, Soukamneuth S, Leonard J, Sepp-Lorenzino L, Clark ED, Lebwohl D, Cohn DM. CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema. N Engl J Med. 2024 Feb 1;390(5):432-441. doi: 10.1056/NEJMoa2309149. PMID: 38294975. New Peanut Allergy Rare After Peanut Introduction in Infants Reviewed by Sarah Spriet Rates of New Peanut Allergy and Discontinuation Following Introduction in High-Risk Infants Banerjee A, Wood R, Dunlop J, Dantzer J, Plesa M, Togias A, Keet C. Rates of New Peanut Allergy and Discontinuation Following Introduction in High-Risk Infants. J Allergy Clin Immunol Pract. 2024 Mar;12(3):645-651.e1. doi: 10.1016/j.jaip.2023.11.035. Epub 2023 Nov 29. PMID: 38036248.   IgE to Food Allergens and Cardiovascular Mortality Reviewed by Gerry Lee IgE to common food allergens is associated with cardiovascular mortality in the National Health and Examination Survey and the Multi-Ethnic Study of Atherosclerosis Keet C, McGowan EC, Jacobs D, Post WS, Richards NE, Workman LJ, Platts-Mills TAE, Manichaikul A,...

Episode 46: Can We Achieve Clinical Remission In Asthma?

24 min

Welcome to another episode of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology! For today’s episode we will be reviewing articles from Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. You can also earn CME credit by listening to this podcast! For information about CME credit, head over to education.acaai.org/allergytalk. Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Reviewed by Iris Otani Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial. Zhang J, Yang X, Chen G, Hu J, He Y, Ma J, Ma Z, Chen H, Huang Y, Wu Q, Liu Y, Yu L, Zhang H, Lai H, Zhang J, Zhai J, Huang M, Zou Z, Tao A. Efficacy and safety of intratonsillar immunotherapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial. Ann Allergy Asthma Immunol. 2024 Mar;132(3):346-354.e1. doi: 10.1016/j.anai.2023.10.029. Epub 2023 Oct 31. PMID: 37913839. Clinical Remission in a Real-World Severe Asthma Registry Reviewed by Tim Chow Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry. McDowell PJ, McDowell R, Busby J, Eastwood MC, Patel PH, Jackson DJ, Mansur A, Patel M, Burhan H, Doe S, Chaudhuri R, Gore R, Dodd JW, Subramanian D, Brown T, Heaney LG; UK Severe Asthma Registry. Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry. Eur Respir J. 2023 Dec 14;62(6):2300819. doi: 10.1183/13993003.00819-2023. PMID: 37857423; PMCID: PMC10719453. More Evidence Against Using Corticosteroids for Anaphylaxis Reviewed by Iris Otani Managing anaphylaxis: Epinephrine, antihistamines, and corticosteroids: More than 10 years of Cross-Canada Anaphyl...

The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries, Episode 3

22 min

The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries Episode 3: Maintenance and Reliever Therapy in Moderate to Severe Asthma   Host: Gerald B. Lee, MD, FACAAI Experts: Leonard B. Bacharier, MD, FACAAI, Alan P. Baptist, MD, MPH, FACAAI   Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: MART therapy, ICS/formoterol, FDA guidelines, pediatric application.   Learning Objectives: Expose the prevalence of asthma and exacerbations in the US Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic Realize both the genomic & nongenomic mechanisms of action of inhaled asthma therapies Analyze the latest expert opinion on treatment of asthma to mitigate morbidity Reference: Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252.   Speaker Disclosures: Gerald B. Lee, MD, FACAAI No relevant financial relationships with ineligible companies to disclose   Leonard B. Bacharier, MD, FACAAI Advisor: DBV Technologies Consultant: AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi Researcher: AstraZeneca, Sanofi Speaker: Regeneron, Sanofi   Alan P. Baptist, MD, MPH, FACAAI Advisor: AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi Researcher: AstraZeneca, Novartis, Regeneron   This podcast miniseries is supported by a grant from AstraZeneca.

The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries, Episode 2

18 min

The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries Episode 2: Implementing an Anti-inflammatory Reliever in Mild Asthma   Host: Gerald B. Lee, MD, FACAAI Experts: William C. Anderson III, MD, FACAAI, Leonard B. Bacharier, MD, FACAAI   Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: anti-inflammatory reliever (AIR), pediatric vs. adult patients, GINA guidelines, insurance challenges.   Learning Objectives: Expose the prevalence of asthma and exacerbations in the US Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic Realize both the genomic & nongenomic mechanisms of action of inhaled asthma therapies Analyze the latest expert opinion on treatment of asthma to mitigate morbidity   Reference: Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252.   Speaker Disclosures: Gerald B. Lee, MD, FACAAI No relevant financial relationships with ineligible companies to disclose   William C. Anderson III, MD, FACAAI Advisor: Genentech, Regeneron, Sanofi   Leonard B. Bacharier, MD, FACAAI Advisor: DBV Technologies Consultant: AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi Researcher: AstraZeneca, Sanofi Speaker: Regeneron, Sanofi   This podcast miniseries is supported by a grant from AstraZeneca.

The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries, Episode 1

13 min

The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries Episode 1: The Limitations of Bronchodilator Only Rescue Therapy   Host: Gerald B. Lee, MD, FACAAI Experts: William C. Anderson III, MD, FACAAI, Alan P. Baptist, MD, MPH, FACAAI   Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: pathophysiology, exacerbations, anti-inflammatory reliever (AIR), SMART therapy.   Learning Objectives: Expose the prevalence of asthma and exacerbations in the US Examine the contribution of fluctuating inflammation to the development of asthma attacks and patient preference when symptomatic Realize both the genomic & nongenomic mechanisms of action of inhaled asthma therapies Analyze the latest expert opinion on treatment of asthma to mitigate morbidity   Reference: Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252.   Speaker Disclosures: Gerald B. Lee, MD, FACAAI No relevant financial relationships with ineligible companies to disclose   William C. Anderson III, MD, FACAAI Advisor: Genentech, Regeneron, Sanofi   Alan P. Baptist, MD, MPH, FACAAI Advisor: AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi Researcher: AstraZeneca, Novartis, Regeneron   This podcast miniseries is supported by a grant from AstraZeneca.

Episode 45 - Should We Wait To Skin Test After A Food Allergy Reaction? AllergyWatch Jan/Feb 2024

24 min

Welcome to Season Three of Allergytalk! Today we joined by Dr. Shyam Joshi, MD, Associate Professor and Section Chief at Oregon Health & Science University and Associate Editor of Allergy Watch. We will be reviewing the January-February issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.  To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Gut microbiota maturity mediates the protective effect of siblings on food allergy. Duration of skin prick test refractory period following food-induced allergic reactions. Clinical and immunological phenotypes of selective IgM deficiency in children: Results from a multicenter study. Please rate our podcast on Apple Podcasts! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee has been a speaker for Novartis. Dr. Fineman: Speaker: Takeda; Research: DBV, Novartis, and Alladapt Dr. Joshi: Advisor: Genentech, Sanofi & Regeneron, Novartis, Takeda; Consultant, Executive Role: Nectar Allergy

Episode 44 - How Does Tryptase Genetics Affect Food Allergy Reactions?

27 min

Welcome to Season Three of Allergytalk! Today we joined by Dr. Shyam Joshi, MD, Associate Professor and Section Chief at Oregon Health & Science University and Associate Editor of Allergy Watch. We will be reviewing the January-February issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.  To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Outcomes of oral food challenges in a real-world setting, with predictors of outcomes. Severe food allergy reactions are associated with α-tryptase. Association of a Housing Mobility Program With Childhood Asthma Symptoms and Exacerbations. Please rate our podcast on Apple Podcasts! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee has been a speaker for Novartis. Dr. Fineman: Speaker: Takeda; Research: DBV, Novartis, and Alladapt Dr. Joshi: Advisor: Genentech, Sanofi & Regeneron, Novartis, Takeda; Consultant, Executive Role: Nectar Allergy

AllergyTalk Special Episode: Preparing For the Allergy/Immunology Boards

41 min

Welcome to a Special Board Review Episode of AllergyTalk! As the fall welcomes a new class of allergy/immunology fellows, the graduating fellows are studying for the fall ABAI board certification exam. I’m excited to be joined by the editorial team of the newly released 5th edition of the ACAAI Review of the Allergy & Immunology Boards, where we’ll talk about how you can prepare for the upcoming board exam! Guests: Joyce Yu, MD Associate Professor of Pediatrics Director, Food Allergy Center Division of Allergy, Immunology and Rheumatology Columbia University Irving Medical Center Ben Prince, MD, MSCI Associate Professor of Pediatrics Associate Division Chief of Research Division of Allergy-Immunology The Ohio State University College of Medicine   Resources for Board Review: Exam Blueprint ACAAI FIT and Board Review Resources (including the board review book) AIM Self-Assessment: Volume One (2023) AAAAI Allergy/Immunology Self Assessment   For information about CME credit, head over to http://education.acaai.org/allergytalk Please rate our podcast on Apple Podcasts! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.   Today’s speakers have the following disclosures: Dr. Lee has been a speaker for Novartis. Dr. Prince is a Data Monitoring Committee Member for Eli Lilly Dr. Yu has no relevant disclosures.

Episode 43 – Does Allergen Immunotherapy Improve Anti-viral Immunity?

20 min

Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! Today we joined by Dr. Sarah Spriet, DO, an allergist/immunologist at the Alexander T. Augusta Military Medical Center in Fort Belvoir, VA and an assistant editor of Allergy Watch. We will be reviewing the November-December 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.  You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Allergen Immunotherapy Enhances Airway Epithelial Antiviral Immunity in Patients with Allergic Asthma (VITAL Study): A Double-Blind Randomized Controlled Trial.  Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation.  Prevalence of CFTR variants in primary immunodeficiency patients with bronchiectasis is an important modifying cofactor. Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.   Today’s speakers have the following disclosures: Drs. Lee and Sp...

Episode 42 – What’s the Best Antibiotic for Kids With Sinusitis?

21 min

Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! Today we joined by Dr. Sarah Spriet, DO, an allergist/immunologist at the Alexander T. Augusta Military Medical Center in Fort Belvoir, VA and an assistant editor of Allergy Watch. We will be reviewing the November-December 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.  You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: The protective effect of moderate maternal peanut consumption on peanut sensitization and allergy.  Hymenoptera venom skin testing: Adopting an accelerated test protocol.  Treatment Failure and Adverse Events After Amoxicillin-Clavulanate vs Amoxicillin for Pediatric Acute Sinusitis.   Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.   Today’s speakers have the following disclosures: Drs. Lee and Spriet have nothing to disclose Dr. Fineman -  Research: DBV, Novartis, Alladapt

Episode 41 – A Promising New Treatment for SCID!

22 min

Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! Today we joined by Dr. Tim Chow, an assistant professor at UT Southwestern and an assistant editor of Allergy Watch. We will be reviewing the July-August 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.  You can also earn CME credit by listening to this podcast! For information about CME credit please visit https://education.acaai.org/allergytalk .  To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.   Racial and Ethnic Disparities in Allergen Immunotherapy Prescription for Allergic Rhinitis.   Human T cell generation is restored in CD3δ severe combined immunodeficiency through adenine base editing.   Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Drs. Lee and Chow have nothing to disclose Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Episode 40 – Intranasal Epinephrine for Anaphylaxis

20 min

Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! Today we joined by Dr. Tim Chow, an assistant professor at UT Southwestern and an assistant editor of Allergy Watch. We will be reviewing the July-August 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.  You can also earn CME credit by listening to this podcast! For information about CME credit please visit https://education.acaai.org/allergytalk. To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Pharmacokinetic and pharmacodynamic comparison of epinephrine, administered intranasally and intramuscularly: An integrated analysis.   Wildfires and the Changing Landscape of Air Pollution-related Health Burden in California.   Differences in Hypersensitivity Reactions to Iodinated Contrast Media: Analysis of the US Food and Drug Administration Adverse Event Reporting System Database.   Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.   Today’s speakers have the following disclosures: Drs. Lee and Chow have nothing to disclose Dr. Fineman...

Episode 39: Should We Pay Teenagers to Carry Epinephrine?

29 min

Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! Today we joined by Dr. Melinda Rathkopf, who is an associate professor at Emory and has had multiple leadership positions at the College, including sitting on the board of regents and chairing the Practice Management Committee. We will be reviewing the May-June 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.  You can earn CME credit by listening to this podcast! For information about CME credit please visit https://education.acaai.org/allergytalk . To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch . Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Food Allergy Management for Adolescents Using Behavioral Incentives: A Randomized Trial.   Early, continuing exposure to cow's milk formula and cow's milk allergy: The COMEET study, a single center, prospective interventional study.   Determinants of lung function across childhood in the Severe Asthma Research Program (SARP) 3.   Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.   Today’s speakers have the following disclosures: Drs. Lee...

Episode 38: Should Immunotherapy Be Offered For Atopic Dermatitis?

28 min

Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! Today we are joined by Dr. Melinda Rathkopf, who is an associate professor at Emory and has had multiple leadership positions at the College, including sitting on the board of regents and chairing the Practice Management Committee. We will be reviewing the May-June 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.  You can earn CME credit by listening to this podcast! For information about CME credit please visit https://education.acaai.org/allergytalk . To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch . Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed:  Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial.   Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms.   The impact of prenatal dog keeping on infant gut microbiota development.   Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.   Today’s speakers have the following disclosures: Drs. Lee an...

Episode 37: Is There a Role For Allergen Immunotherapy in Seasonal Allergic Asthma? Jan/Feb 2023

26 min

Today we joined by Dr. Samanta Knox, MD from Gunderson Health System in La Crosse, WI where we review the Jan-Feb 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.   You can earn CME credit by listening to this podcast! For information about CME credit please visit https://education.acaai.org/allergytalk To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch   Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!   Articles Reviewed: Allergen immunotherapy effectively reduces the risk of exacerbations and lower respiratory tract infections in both seasonal and perennial allergic asthma: a nationwide epidemiological study.   Prospective evaluation of tolerance to unheated milk-boiled egg after baked milk-egg tolerance under 2 years.   Multiscale study of the oral and gut environments in children with high- and low-threshold peanut allergy.   Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.   Today’s speakers have the following disclosures: Drs. Lee and Knox have nothing to disclose Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Episode 36: How Safe Are Oral Corticosteroids? Jan/Feb 2023

22 min

Today we joined by Dr. Samanta Knox, MD from Gunderson Health System in La Crosse, WI where we review the Jan-Feb 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.  You can earn CME credit by listening to this podcast! For information about CME credit, go to https://education.acaai.org/allergytalk. To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch. Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Race and ethnicity define disparate clinical outcomes in chronic rhinosinusitis.   Atopic dermatitis and risk of autoimmune conditions: Population-based cohort study.   Low-dose oral corticosteroids in asthma associates with increased morbidity and mortality.   Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Drs. Lee and Knox have nothing to disclose Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Episode 35: Can Azithromycin Help Poorly Controlled Childhood Asthma?

21 min

Originally Recorded 4/18/2023   Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! For this episode we welcome Dr. Shyam Joshi, MD from Oregon Health and Science University and will be reviewing three articles from the Nov-Dec 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. Articles Reviewed: In Kids With Allergic Rhinitis, Remember To Address Sleep Problems!   Allergic disease, sleep problems, and psychological distress in children recruited from the general community.   Azithromycin as an Option for Poorly Controlled Childhood Asthma    Azithromycin for Poorly Controlled Asthma in Children: A Randomized Controlled Trial.   Data Suggest ‘Real-World Benefit’ of Early Introduction   Changes in Australian food anaphylaxis admission rates following introduction of updated allergy prevention guidelines.   Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org   ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee has nothing to disclose Dr. Joshi has the following disclosures: Advisory board: Takeda Leo Pharma Sanofi/Regeneron Nectar Allergy Cogent Clinical trial funding: GlaxoSmithKline Sanofi Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Episode 34: Are Nasal Polyps an Autoimmune Disease?

22 min

Originally Recorded 4/18/2023   Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! For this episode we welcome Dr. Shyam Joshi, MD from Oregon Health and Science University and will be reviewing three articles from the Nov-Dec 2022 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. Articles Reviewed:   Combined ICS/SBA Reduces Asthma Exacerbations   Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma. CRSwNP Patients have Impaired Sense of Smell and Taste   Improvement in patient-reported "taste" and association with smell in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS-24 and SINUS-52 trials.   Loss of smell in patients with aspirin-exacerbated respiratory disease impacts mental health and quality of life.   Anti-dsDNA IgG May Predict Nasal Polyp Recurrence   Prognostic factors for polyp recurrence in chronic rhinosinusitis with nasal polyps.   Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org   ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following disclosures: Dr. Lee has nothing to disclose Dr. Joshi has the following disclosures: Advisory board: Takeda Leo Pharma Sanofi/Regeneron Nectar Allergy Cogent Clinical trial fun...

Episode 33: Are We Testing for Hymenoptera Backwards?

21 min

Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue! Today we joined by Dr. Vivan Hernandez-Trujillo, MD from Nicklaus Children’s Hospital in Miami, Florida where we review the July-Aug 2022 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.  You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles! Articles Reviewed: Combining Discordant Serum IgE and Skin Testing Improves Diagnostic and Therapeutic Accuracy for Hymenoptera Venom Hypersensitivity Immunotherapy. Safety of Live Attenuated Influenza Vaccine in Children With Asthma. Obesity alters pathology and treatment response in inflammatory disease.   Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.   Today’s speakers have the following disclosures: Dr. Lee has nothing to disclose Dr. Hernandez-Trujillo:  Speaker Takeda, CSL Advisory boards Takeda, Regeneron, Sanofi Consultant  Kaleo, Pharming, Enzyvant, National Peanut Board, Allergy and Asthma Network Dr. Fineman: Spe...

Episode 27: How Important Is Family History in Infant Peanut Allergy?

24 min

Originally recorded 11/24/21 For today’s episode we will be reviewing three articles from the July-Aug 2021 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. Is Alpha-Gal Really a Problem in Patients with Food Allergy? Diagnostic testing for galactose-alpha-1,3-galactose, United States, 2010 to 2018. Family history alone isn’t a Risk Factor for Peanut Allergy Age and eczema severity, but not family history, are major risk factors for peanut allergy in infancy. Peripheral eosinophil counts: a moving target Variability in Blood Eosinophil Counts in Patients with Eosinophilic Asthma.   Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.   At the time of recording, the speakers had the following disclosures: Dr. Lee has nothing to disclose Dr. Kalangara Speaker and Consultant: GlaxoSmithKline Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst

Omalizumab for Food Allergy Part 2: Implementation Into Practice

29 min

Welcome to a special 2 part episode of Allergytalk! On February 16, 2024, the FDA announced the approval of the first biologic medication to treat patients with food allergy, omalizumab! In second part of a 2 part series, we will discuss important considerations in implementing omalizumab for food allergy in your practice. Speakers: Dr. Sharon Chinthrajah, MD, an associate professor at Stanford University and the Director of the Sean N Parker Center for Allergy and Asthma Research. She is a co-chair of the OUtMATCH study. Dr. Brian Vickery, MD, the Marcus Professor of Pediatric Immunology and Division Chief at Emory University and Children’s Healthcare of Atlanta. He was one of the site investigators of the OUtMATCH study. Important Links: Wood RA, Togias A, Sicherer SH, Shreffler WG, Kim EH, Jones SM, Leung DYM, Vickery BP, Bird JA, Spergel JM, Iqbal A, Olsson J, Ligueros-Saylan M, Uddin A, Calatroni A, Huckabee CM, Rogers NH, Yovetich N, Dantzer J, Mudd K, Wang J, Groetch M, Pyle D, Keet CA, Kulis M, Sindher SB, Long A, Scurlock AM, Lanser BJ, Lee T, Parrish C, Brown-Whitehorn T, Spergel AKR, Veri M, Hamrah SD, Brittain E, Poyser J, Wheatley LM, Chinthrajah RS. Omalizumab for the Treatment of Multiple Food Allergies. N Engl J Med. 2024 Feb 25. https://www.nejm.org/doi/pdf/10.1056/NEJMoa2312382 Updated FDA label for omalizumab: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/103976s5245lbl.pdf Please rate our podcast on iTunes! Please give us feedback, corrections, and suggestions! Email feedback to: allergytalk@acaai.org ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced. Today’s speakers have the following di...

See all 100 episodes

–

0 ratings from members

5
4
3
2
1

Rate this podcast

Log in to rate and review the shows you listen to.

No reviews yet — be the first member to rate "AllergyTalk".

This podcast, its content and its artwork are not owned by, affiliated with, or endorsed by Castquire.

Keep listening

Discover more podcasts like this.

Up next

  1. Nothing queued. Use + Queue on any episode to line it up.

0:00 0:00